Corporate News - 22 October 2021

BPL to support the Immune Deficiency Foundation Research Grant Program

Download PDF

22 October 2021

Bio Products Laboratory (BPL), a leading manufacturer of plasma-derived protein therapies, with US Offices in Durham, NC, announced today their support of the Immune Deficiency Foundation (IDF) Research Grant Program.    

The IDF Research Grant Program is designed to encourage and support patient-oriented research on primary immunodeficiencies (P.I.), including well-defined research projects with a specified benefit for improving the treatment, health, disease management, or diagnosis of people with P.I. management or diagnosis of people with primary immunodeficiency diseases.

"We're excited to support IDF's grant program with this unrestricted grant," said Eric Wolford, PharmD, Vice President of the Global Medical group for BPL. "Funding research that ultimately helps PI patients live healthier, happier lives is a goal we share with IDF.” 

According to John Seymour, Chair of IDF's Board of Trustees, "This initiative represents an important, collaborative opportunity to support studies that contribute to the body of medical knowledge in P.I.  The research funded through this program will advance IDF's mission to improve the diagnosis, treatment, and quality of life of persons with primary immunodeficiencies." 

Primary immunodeficiencies are a group of more than 400 rare, chronic disorders in which part of the body's immune system is missing or functions improperly. Because one of the most critical functions of the normal immune system is to protect against infection, patients with P.I. commonly have an increased vulnerability to recurrent and sometimes severe and debilitating infections.

For more information about the IDF Research Grant Program, contact Christopher Scalchunes at cscalchunes@primaryimmune.org .

 

About Bio Products Laboratory (BPL)

Recognizing the power of plasma and with many years of experience in the industry, BPL supplies high-quality plasma-derived medicines to meet the needs of clinicians, patients, and customers globally. Headquartered in the United Kingdom and with plasma collection centers across the United States, we are dedicated to producing medicines for the treatment of immune deficiencies, bleeding disorders, infectious diseases, and critical care. BPL invests in the latest R&D, technology, and manufacturing methods and continuously adapts to ensure that we continue to serve all our stakeholders effectively. For more information, visit http://www.bplgroup.com or https://www.bpl-us.com/

BPL consists of two operating divisions — BPL Plasma and BPL Therapeutics. BPL Plasma, headquartered in Austin, Texas and operating in the USA, collects plasma from donors in around 27 centers across the U.S. BPL Plasma employs over 900 staff to support the needs of donors and to ensure high-quality plasma collection in all their centers. Plasma collection is regulated by both FDA and MHRA, and BPL Plasma follows industry guidelines. BPL Plasma operates clean and safe plasma facilities, staffed with trained personnel, dedicated to supporting donors through the process that leads to the donation of plasma. Plasma is shipped to the headquarters of BPL Therapeutics in Elstree, United Kingdom. The plasma is fractionated, purified, and filled through the efforts of our over 1,000 employees involved in production, quality, R&D, commercial, customer services, and administrative activities. BPL's plasma-derived medicines are commercially available in the U.K., USA, and 30 plus other countries around the world through our network of local affiliates and distribution partners.

About Immune Deficiency Foundation 

The Immune Deficiency Foundation improves the diagnosis, treatment, and quality of life of people affected by primary immunodeficiency through fostering a community empowered by advocacy, education, and research. Individuals affected by P.I. often find it difficult to receive a proper diagnosis, treatment, and specialized healthcare. IDF estimates that the average length of time between the onset of symptoms and diagnosis is between nine and 15 years. Patients also experience difficulties financing their healthcare, finding educational materials, or locating others with whom to share their experiences. IDF helps individuals overcome these difficulties.

IDF provides accurate and timely information for patients and families living with P.I. and offers valuable resources. IDF…  

  • Helps the patient and medical community gain a broader understanding of P.I. through education and outreach efforts.
  • Promotes, participates in, and conducts research that has helped characterize P.I. and given patients and physicians substantially improved treatment options.
  • Addresses patient needs through public policy programs by focusing on issues such as insurance reimbursement, patient confidentiality, ensuring the safety and availability of immunoglobulin therapy, and maintaining and enhancing patient access to treatment options.
  • Tens of thousands of individuals and families affected by P.I. depend on IDF for advocacy, education, and empowerment.  
  • IDF does not charge patients or healthcare professionals for the educational materials or specialized programming that it provides. This is possible because of the generosity of the donors and sponsors who make unrestricted gifts to IDF.

Learn more at www.primaryimmune.org.